Sana Biotechnology Inc.
Organization details
- Legal name
- Sana Biotechnology Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Seattle
- Headquarters state / province
- Washington
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- SANA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001770121
- EIN
- 83-1381173
- Wikidata ID
- Q106301980
Board of directors
-
Alise Reicin · DirectorSince 2023
-
Douglas G. Cole · DirectorSince 2023
-
Hans Edgar Bishop · DirectorSince 2023
-
Joshua H. Bilenker · DirectorSince 2023
- Since 2023
-
Michelle Seitz · DirectorSince 2023
-
Patrick Y. Yang · DirectorSince 2023
-
Richard Mulligan · Director · Head of SanaXSince 2023
-
Robert L. Rosiello · DirectorSince 2025
- Since 2023
-
Steve Harr · Director · President & CEOSince 2023
Chief executives
Director election results
Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
67.3%
-
85.8%
-
91.9%
Board connections
8 of this board's directors also sit on 22 other boards. 12 are in the same sector.
-
Lyell Immunopharma Inc. Same sectorvia Hans Edgar Bishop and Robert Nelsen
- via Hans Edgar Bishop
-
Bausch Health Companies Inc. Same sectorvia Richard Mulligan
-
City Therapeutics Inc. Same sectorvia Robert Nelsen
- via Mary Agnes Wilderotter
-
Denali Therapeutics Inc. Same sectorvia Douglas G. Cole
- via Mary Agnes Wilderotter
-
Foghorn Therapeutics Inc. Same sectorvia Douglas G. Cole
- via Mary Agnes Wilderotter
- via Michelle Seitz
-
Immatics N.V. Same sectorvia Alise Reicin
- via Richard Mulligan
-
Kardigan Inc. Same sectorvia Robert Nelsen
- via Mary Agnes Wilderotter
- via Michelle Seitz
- via Michelle Seitz
- via Mary Agnes Wilderotter
-
Prime Medicine Inc. Same sectorvia Robert Nelsen
-
Q32 Bio Inc. Same sectorvia Alise Reicin
-
Seres Therapeutics Inc. Same sectorvia Robert L. Rosiello
-
Tectonic Therapeutic Inc. Same sectorvia Alise Reicin
-
Vir Biotechnology Inc. Same sectorvia Robert Nelsen
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 5, 2026 | Hans Edgar Bishop Director | Grant or award | +8,680 | — | — |
| Aug 27, 2026 | PATEL DHAVALKUMAR DHIRAJLAL Officer (EVP, Chief Scientific Officer) | Shares withheld for tax | −41,158 | $4.11 | $169,159 |
| Aug 26, 2026 | PATEL DHAVALKUMAR DHIRAJLAL Officer (EVP, Chief Scientific Officer) | Option exercise | +125,000 | — | — |
| Jul 6, 2026 | Hans Edgar Bishop Director | Grant or award | +6,297 | — | — |
| Apr 6, 2026 | Hans Edgar Bishop Director | Grant or award | +7,763 | — | — |
| Mar 9, 2026 | Steve Harr Director, Officer (President & CEO) | Shares withheld for tax | −11,526 | $3.13 | $36,076 |
| Mar 9, 2026 | Wyrick Susan D. Officer (See Remarks) | Shares withheld for tax | −3,342 | $3.13 | $10,460 |
| Mar 9, 2026 | Steve Harr Director, Officer (President & CEO) | Shares withheld for tax | −12,819 | $3.10 | $39,739 |
| Mar 9, 2026 | Wyrick Susan D. Officer (See Remarks) | Shares withheld for tax | −1,045 | $3.10 | $3,240 |
| Mar 7, 2026 | Steve Harr Director, Officer (President & CEO) | Option exercise | +50,000 | — | — |
| Mar 7, 2026 | Wyrick Susan D. Officer (See Remarks) | Option exercise | +3,250 | — | — |
| Mar 6, 2026 | Steve Harr Director, Officer (President & CEO) | Option exercise | +41,666 | — | — |
| Mar 6, 2026 | Wyrick Susan D. Officer (See Remarks) | Option exercise | +10,416 | — | — |
| Mar 3, 2026 | Wyrick Susan D. Officer (See Remarks) | Shares withheld for tax | −491 | $3.91 | $1,920 |
| Mar 2, 2026 | Wyrick Susan D. Officer (See Remarks) | Option exercise | +1,525 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Sana Biotechnology Inc.
Who is the CEO of Sana Biotechnology Inc.?
Steve Harr is Sana Biotechnology Inc.'s President & CEO.
How many directors are on Sana Biotechnology Inc.'s board?
Sana Biotechnology Inc.'s board has 11 directors: Alise Reicin, Douglas G. Cole, Hans Edgar Bishop, Joshua H. Bilenker, Mary Agnes Wilderotter, Michelle Seitz, Patrick Y. Yang, Richard Mulligan, Robert L. Rosiello, Robert Nelsen and 1 other.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="sana-biotechnology-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.